168 related articles for article (PubMed ID: 18070197)
1. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Li H; Raia V; Bertolini F; Price DK; Figg WD
BJU Int; 2008 Apr; 101(7):884-8. PubMed ID: 18070197
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
[TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
[TBL] [Abstract][Full Text] [Related]
6. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
7. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
10. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A; Sternberg CN; Skoneczna I; Kovel S
BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting.
Santini D; Zoccoli A; Gregorj C; Di Cerbo M; Iuliani M; Pantano F; Zamarchi R; Sergi F; Flammia G; Buscarini M; Rizzo S; Cicero G; Russo A; Vincenzi B; Avvisati G; Tonini G
Oncology; 2013; 85(6):342-7. PubMed ID: 24335337
[TBL] [Abstract][Full Text] [Related]
14. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
Strijbos MH; Gratama JW; Schmitz PI; Rao C; Onstenk W; Doyle GV; Miller MC; de Wit R; Terstappen LW; Sleijfer S
Eur J Cancer; 2010 Jul; 46(11):2027-35. PubMed ID: 20399640
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
17. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
